S&P Futures
3,907.50-15.00(-0.38%)Dow Futures
31,904.00-12.00(-0.04%)Nasdaq Futures
13,152.25-149.75(-1.13%)
Cleveland BioLabs, Inc. (CBLI)
5.82 0.00 (0.00%)
Pre-Market: 6:47AM EST
Chart Events
Performance Outlook
| Previous Close | 5.45 |
| Open | 5.75 |
| Bid | 0.00 x 1800 |
| Ask | 5.96 x 1400 |
| Day's Range | 5.70 - 6.28 |
| 52 Week Range | 1.27 - 10.97 |
| Volume | 531,128 |
| Avg. Volume | 457,553 |
| Market Cap | 77.849M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings Date | May 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / February 24, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Cleveland BioLabs, Inc. (NASDAQ:CBLI) relating to the creation of a combined company between the Company and Cytocom, Inc.
- ACCESSWIRE
Cleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common Stock
BUFFALO, NY / ACCESSWIRE / February 23, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has closed its previously announced registered direct offering for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
- ACCESSWIRE
Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
